|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 401/04 |
| (11) | Number of the document | 3286176 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16718016.5 |
| Date of filing the European patent application | 2016-04-13 | |
| (97) | Date of publication of the European application | 2018-02-28 |
| (45) | Date of publication and mention of the grant of the patent | 2020-01-15 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/IB2016/052107 |
| Date | 2016-04-13 |
| (87) | Number | WO 2016/170451 |
| Date | 2016-10-27 |
| (30) | Number | Date | Country code |
| 201562152108 P | 2015-04-24 | US |
| (72) |
HANSEN, Eric Christian, US
SEADEEK, Christopher Scott, US
|
| (73) |
Pfizer Inc.,
235 East 42nd Street, New York, NY 10017,
US
|
| (54) | CRYSTALLINE FORMS OF 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA MALEATE |
| CRYSTALLINE FORMS OF 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA MALEATE |